Loading clinical trials...
Loading clinical trials...
An Open-label, Intra-participant Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants With Immune Thrombocytopenia
Conditions
Interventions
NVG-2089
Locations
1
United States
Nuvig Site
Westbury, New York, United States
Start Date
September 30, 2025
Primary Completion Date
June 30, 2026
Completion Date
December 31, 2026
Last Updated
July 31, 2025
NCT07294365
NCT07175493
NCT06888960
NCT06371417
NCT06853444
NCT06799611
Lead Sponsor
Nuvig Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions